Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Tweeting: Five Twitter Moments That Highlight The Perils Of The Platform

Executive Summary

Scrip takes a broad look at some controversial Twitter moments that pharma should be watchful of  - words once let out of the cage cannot be whistled back again.

You may also be interested in...



Gottlieb Wants His US FDA Team To Stay Together After He Departs

INFOGRAPHIC: Wait time for confirmed commissioner has been trending down.

Senate Drug Pricing Hearing Looms As Unparalleled Event For Pharma

From Vioxx to EpiPen, industry has been called in to testify before Congress on a range of issues. But with seven big pharma leaders having accepted the Senate Finance Committee's invitation Feb. 26, the stage is set for some exceptional political theater.

Expert Panel Affirms ‘Continued Marketing’ Of Ambrisentan, Everolimus In India

Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124950

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel